Shamburg News · 8-K filed Nov 10, 2026, 4:05 PM EST

Braveheart Bio Reports Third Quarter 2026 Financial Results and Business Update

BRVE · Braveheart Bio, Inc.

  • Earnings
  • Materiality: high

Braveheart Bio, Inc. reported unaudited results for the quarter ended September 30, 2026, with a net loss of $26.5 million, or $0.51 per share, compared with a net loss of $59.1 million, or $10.05 per share, in the same period of 2025. Research and development expenses were $17.5 million and general and administrative expenses were $12.6 million, and no in-process research and development expense was recorded versus $58.8 million a year earlier. Cash, cash equivalents and investments were $503.5 million as of September 30, 2026, which the company expects to fund operations into 2029.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001628280-26-072702.

Written from the filing by Shamburg Markets. Figures are as reported by the company.